Figure 2.

Increased RUNX2 expression results in resistance to docetaxel in vitro. (A) LNCaP-V or LNCaP-R cells were exposed to docetaxel for 48 h before XTT assay. Results shown are mean±s.e. for three independent experiments. Inset is representative western blot showing RUNX2 protein expression in stable cell lines. (B) LNCaP-R cells were treated with either scrambled siRNA or RUNX2 siRNA, and response to docetaxel was measured using an XTT assay after 48 h. Results shown are mean±s.e. of three independent experiments. Inset is representative western blot showing RUNX2 expression in 1 – LNCaP-R cells, 2 – LNCaP-R cells treated with scrambled siRNA and 3 – LNCaP-R cells treated with RUNX2 siRNA. (C) LNCaP cells were treated with scrambled or RUNX2 siRNA and viability following bicalutamide measured after 24 and 48 h using an XTT assay. Results shown are mean±s.e. of three independent experiments. (D) LNCaP-V or LNCaP-R cells were counted using a trypan blue exclusion assay following chronic hypoxia (0.1% O₂ for 72 h). Results shown are mean±s.e. of three independent experiments. (E) PC3 cells were treated with scrambled siRNA or RUNX2 siRNA, and response to docetaxel was measured using an XTT assay. Results shown are mean±s.e. of three independent experiments. (F) LNCaP cells were transfected with scrambled siRNA or RUNX2 siRNA before hypoxia exposure (0.1% O₂) for 2 h prior to treatment with docetaxel. Cell viability was measured after 48 h using an XTT assay. ^*P⩽0.05, ^**P⩽0.01 and ^***P⩽0.001 (two-way ANOVA).